On Tuesday, Regenxbio Inc (NASDAQ: RGNX) was -7.00% drop from the session before settling in for the closing price of $10.00. A 52-week range for RGNX has been $8.53 – $28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 72.63%. When this article was written, the company’s average yearly earnings per share was at 21.64%. With a float of $44.84 million, this company’s outstanding shares have now reached $49.53 million.
The extent of productivity of a business whose workforce counts for 344 workers is very important to gauge. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Regenxbio Inc stocks. The insider ownership of Regenxbio Inc is 9.50%, while institutional ownership is 90.28%. The most recent insider transaction that took place on Oct 01 ’24, was worth 101,052. In this transaction Director of this company sold 10,000 shares at a rate of $10.11, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Director sold 10,000 for $11.56, making the entire transaction worth $115,588. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 21.64% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
You can see what Regenxbio Inc (RGNX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
The latest stats from [Regenxbio Inc, RGNX] show that its last 5-days average volume of 0.65 million was superior to 0.63 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 45.99%. Additionally, its Average True Range was 0.80.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 11.21%, which indicates a significant decrease from 13.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.28% in the past 14 days, which was higher than the 67.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.93, while its 200-day Moving Average is $13.99. Now, the first resistance to watch is $9.76. This is followed by the second major resistance level at $10.21. The third major resistance level sits at $10.53. If the price goes on to break the first support level at $8.99, it is likely to go to the next support level at $8.67. The third support level lies at $8.22 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
There are 49,545K outstanding shares of the company, which has a market capitalization of 460.77 million. As of now, sales total 90,240 K while income totals -263,490 K. Its latest quarter income was 24,200 K while its last quarter net income were -59,600 K.
